C07K 16/249
Interferons
Official title: {Interferons}
C07K16/249 (Interferons) appears on 241 US grants and 381 published applications in this corpus.
Search patents in C07K- Granted patents
- 241
- Published applications
- 381
- Assignees
- 190
- Inventors
- 614
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 2 | 0 |
| 1983 | 3 | 0 |
| 1984 | 3 | 0 |
| 1985 | 2 | 0 |
| 1986 | 2 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 4 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 4 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 6 | 0 |
| 1998 | 3 | 0 |
| 1999 | 5 | 0 |
| 2000 | 5 | 0 |
| 2001 | 4 | 1 |
| 2002 | 4 | 5 |
| 2003 | 2 | 21 |
| 2004 | 5 | 12 |
| 2005 | 3 | 16 |
| 2006 | 5 | 15 |
| 2007 | 7 | 17 |
| 2008 | 6 | 13 |
| 2009 | 7 | 13 |
| 2010 | 7 | 13 |
| 2011 | 8 | 25 |
| 2012 | 7 | 19 |
| 2013 | 10 | 16 |
| 2014 | 11 | 13 |
| 2015 | 5 | 18 |
| 2016 | 9 | 17 |
| 2017 | 9 | 15 |
| 2018 | 10 | 11 |
| 2019 | 6 | 19 |
| 2020 | 9 | 19 |
| 2021 | 12 | 12 |
| 2022 | 9 | 23 |
| 2023 | 9 | 9 |
| 2024 | 9 | 18 |
| 2025 | 14 | 12 |
| 2026 | 5 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Combination immunotherapy15 Sep 2026US 12,735,466 B2The Regents of the University of California
- Composition for cancer diagnosis18 Aug 2026US 12,710,425 B2Acurasysbio Co., Ltd.
- Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain28 Jul 2026US 12,692,307 B2Gi Innovation, Inc.
- Methods of high-throughput identification of T cell epitopes by capturing cytokines on the surface of antigen-presenting cells12 May 2026US 12,624,349 B2Dana-Farber Cancer Institute, Inc.
- Anti-interferon gamma antibodies and uses thereof20 Jan 2026US 12,528,862 B2Elixiron Immunotherapeutics (Hong Kong) Limited
- Intra-striatal co-transplantation of autologous treg and mda cells in parkinson's disease cell therapy8 Oct 2026US 2026/0306543 A1The McLean Hospital Corporation
- Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an il-2 mutant and a cd80 extracellular domain8 Oct 2026US 2026/0308251 A1Gi Innovation, Inc.
- Use of interferon-gamma inhibitors to reduce heart damage after myocardial infarction6 Aug 2026US 2026/0226153 A1Northwestern University
- Affinity and functional based screening of t cell receptor repertoire using three-dimensional shaped particles30 Jul 2026US 2026/0218282 A1The Regents of the University of California
- Clec9a binding agents7 May 2026US 2026/0124298 A1Orionis Biosciences BV
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001
- Polynucleotides encoding improved humanized immunoglobulins1,258US 5,693,761 AProtein Design Labs, Inc. · 1997